NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has signed an agreement to market Axiogenesis' mouse-induced pluripotent stem cell-derived cardiomyocytes and smooth muscle cells for preclinical cardiotoxicity screening.

The Sigma Life Science business of Sigma-Aldrich will offer the products as ready-to-order cells, application-specific kits, and custom services. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.